Stockscreener 앱 받기
24.43
9.42%
-2.54
시간 외 거래:
24.90
0.47
+1.92%
전일 마감가:
$26.97
열려 있는:
$25
하루 거래량:
79,817
Relative Volume:
1.31
시가총액:
$274.14M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-12.00%
1개월 성능:
+24.96%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$24.00
$26.39
1주일 범위
$23.42
$28.78
52주 변동 폭
$11.17
$29.27
Palvella Therapeutics Inc Stock (PVLA) Company Profile
명칭
Palvella Therapeutics Inc
전화
(484) 253-1461
주소
125 STRAFFORD AVE, WAYNE
PVLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
24.43 | 274.14M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-26 | 개시 | Stifel | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-02-05 | 개시 | TD Cowen | Buy |
| 2024-12-26 | 개시 | H.C. Wainwright | Buy |
| 2024-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 개시 | Jefferies | Buy |
| 2018-01-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-30 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-05 | 재개 | ROTH Capital | Buy |
| 2015-08-12 | 개시 | JMP Securities | Mkt Outperform |
| 2015-07-27 | 개시 | Oppenheimer | Outperform |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
모두보기
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella Therapeutics Announces Late-Breaking Presentation at Global Pediatric Dermatology Congress - MSN
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology - The Manila Times
Groundbreaking Phase 3 Results: First-Ever Treatment for Rare Lymphatic Disease Heads to Major Congress - Stock Titan
Palvella Therapeutics (NASDAQ:PVLA) Given “Buy” Rating at HC Wainwright - Defense World
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Is Palvella Therapeutics Inc. (PVLA) the Best Performing NASDAQ Stock So Far in 2025? - Insider Monkey
Stifel maintains $45 target on Palvella Therapeutics stock By Investing.com - Investing.com Canada
Stifel maintains $45 target on Palvella Therapeutics stock - Investing.com
Earnings call transcript: Palvella Therapeutics Q4 2024 reveals strategic focus By Investing.com - Investing.com South Africa
Earnings call transcript: Palvella Therapeutics Q4 2024 reveals strategic focus - Investing.com
Palvella Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Palvella Therapeutics Reports 2024 Financial Results and Updates - TipRanks
PALVELLA THERAPEUTICS, INC. SEC 10-K Report - TradingView
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Palvella Therapeutics to Announce 2024 Financial Results and Host Investor Call on March 31, 2025 - MSN
Palvella Therapeutics (PVLA) to Release Earnings on Monday - Defense World
Palvella Therapeutics Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Brokerages Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $43.20 - Defense World
Palvella Therapeutics (PVLA) Projected to Post Earnings on Monday - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Stifel Nicolaus - Defense World
Is Palvella Therapeutics (PVLA) the Best Performing Stock So Far in 2025? - Insider Monkey
Stifel Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Stifel Initiates Palvella Therapeutics at Buy With $45 Price Target - MarketScreener
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Jones Trading - Defense World
Stifel analysts initiate Palvella Therapeutics stock with Buy, $45 target By Investing.com - Investing.com Canada
Jones Trading Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Stifel initiates Palvella Therapeutics with a buy, $45 target By Investing.com - Investing.com Canada
Stifel analysts initiate Palvella Therapeutics stock with Buy, $45 target - Investing.com
Stifel initiates Palvella Therapeutics with a buy, $45 target - Investing.com
Palvella Therapeutics initiated with a Buy at Stifel - TipRanks
Palvella Therapeutics (PVLA) Projected to Post Earnings on Thursday - Defense World
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 - GlobeNewswire
Palvella Therapeutics, Inc. Scheduled to Report Full Year 2024 Financial Results on March 31, 2025 - Nasdaq
Rare Disease Leader Palvella Therapeutics Unveils 2024 Financial Performance March 31 - StockTitan
Lucid Capital sets $49 target on Palvella Therapeutics stock By Investing.com - Investing.com UK
Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well - Yahoo Finance
Palvella Therapeutics Insider Confidence Rewarded, Stock Hits US$308m Market Cap - simplywall.st
Pieris Pharmaceuticals stock soars to 52-week high of $29.01 - Investing.com
PavellaUndiscovered Biotechnology Stock - TradingView
PalvellaUndiscovered Biotechnology Stock - Barchart
Palvella Therapeutics (NASDAQ:PVLA) Coverage Initiated at Scotiabank - Defense World
Scotiabank Initiates Coverage of Palvella Therapeutics (PVLA) with Sector Outperform Recommendation - Nasdaq
Scotiabank sets Palvella stock to Sector Outperform, $50 target - Investing.com
Scotiabank sets Palvella stock to Sector Outperform, $50 target By Investing.com - Investing.com UK
Palvella Therapeutics initiated with an Outperform at Scotiabank - TipRanks
Pieris Pharmaceuticals stock hits 52-week high at $22.56 By Investing.com - Investing.com Canada
Pieris Pharmaceuticals stock hits 52-week high at $22.56 - Investing.com
Palvella Therapeutics Enhances Investor Relations with New Presentation - TipRanks
Why Palvella Therapeutics, Inc. (PVLA) is Skyrocketing So Far in 2025 - MSN
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Palvella Therapeutics Inc (PVLA) 재무 분석
Palvella Therapeutics Inc (PVLA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):